|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
7,8-Dihydroxyflavone (7,8-DHF), as a high-affinity TrkB receptor agonist, has been extensively explored in many human disorders involving brain-derived neurotrophic factor (BDNF) such as Alzheimer's disease, Parkinson's disease, depression, and obesity.
|
31384856 |
2019 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD), most tauopathies, and other neurodegenerative diseases are highly associated with impaired neurotrophin regulation and imbalanced neutrophin distribution.
|
27975267 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) models were established by injecting Aβ(1-42) into the rat hippocampus and the effects of learning and memory were observed by a Morris water maze test, immunohistological alterations, and correlative indicators covering nerve growth (brain-derived neurotrophic factor, glial-cell-derived trophic factor, and nerve growth factor), interleukin 1β, tumor necrosis factor, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), glial fibrillary acidic protein (GFAP), and microglial CD11b in AD rats.
|
29714500 |
2018 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's disease is marked by the presence of amyloid-beta (Aβ) plaques, elevated central cytokine levels, dysregulation of BDNF-related gene expression, and cognitive decline.
|
30031883 |
2019 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Brain-derived neurotrophic factor gene polymorphisms in Japanese patients with sporadic Alzheimer's disease, Parkinson's disease, and multiple system atrophy.
|
15838855 |
2005 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BDNF Val66Met was analyzed in 211 patients with AD and in 402 aged healthy control subjects.
|
21044653 |
2011 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has previously been implicated in Alzheimer's disease (AD)-related cognitive impairment.
|
23769397 |
2013 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
BDNF levels are lower in the brains of individuals with Alzheimer's disease (AD), suggesting a pathogenic involvement.
|
25954034 |
2015 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Brain-derived neurotrophic factor (BDNF) is associated with the risk for Alzheimer's disease and type 2 diabetes.
|
27553771 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor and is known to possess anti-obesity, anti-diabetic actions and is believed to have a role in memory and Alzheimer's disease.
|
28315336 |
2017 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.
|
28720165 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin-related kinase B (TrkB), have emerged as key regulators of brain plasticity and represent disease-modifying targets for several brain disorders, including Alzheimer's disease and major depressive disorder.
|
28831019 |
2017 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Brain-derived neurotrophic factor (BDNF) gene delivery to the entorhinal cortex is a candidate for treatment of Alzheimer's disease (AD) to reduce neurodegeneration that is associated with memory loss.
|
29535375 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Brain-derived neurotrophic factor (BDNF) is a neutrotrophic factor essential for the survival and differentiation of neurons and is considered a key target in the pathophysiology of various neurodegenerative diseases, as for example AD.
|
30428894 |
2018 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Brain-derived neurotrophic factor (BDNF), an essential factor for maintaining brain functions, has been reported to be reduced in various neurological diseases, including Alzheimer's disease and major depression.
|
30753865 |
2019 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Neurotrophin Receptor p75 mRNA Level in Peripheral Blood Cells of Patients with Alzheimer's Disease.
|
30977102 |
2019 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
BDNF total long 3' transcript expression was significantly lower in those with early AD neuropathology, compared to those without any neuropathology (p = 0.021).
|
31127785 |
2019 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
BDNF/TrkB neurotrophic signaling regulates neuronal development, differentiation, and survival, and deficient BDNF/TrkB activity underlies neurodegeneration in Alzheimer's disease (AD).
|
31315045 |
2019 |
|
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Neurotrophin receptor p75 (p75<sup>NTR</sup>) is a receptor for Aβ and mediates Aβ neurotoxicity, implying that p75<sup>NTR</sup> may mediate Aβ-induced tau phosphorylation in AD.
|
31394202 |
2019 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Val66Met Polymorphism in BDNF Has No Sexual and APOE ε4 Status-Based Dimorphic Effects on Susceptibility to Alzheimer's Disease: Evidence From an Updated Meta-Analysis of Case-Control Studies and High-Throughput Genotyping Cohorts.
|
28984138 |
2018 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A larger group of FTLD patients (n = 194) and controls (n = 396; 162 healthy subjects and 234 Alzheimer's disease (AD) patients) underwent genetic analyses, considering BDNF polymorphisms (Val66Met, rs2049045 C/G, G11757C).
|
22596272 |
2012 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A marked decrease in the expression of miR-29c was observed in the AD group compared with the normal control group, accompanied by a decreased in the expression of BDNF.
|
25815896 |
2015 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A meta-analysis of BDNF levels between early AD and controls showed statistically significantly higher levels (SMD [95 % CI]: 0.72 [0.31, 1.13]) with no heterogeneity.
|
27815832 |
2017 |
|
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A molecular fingerprint strikingly similar to that of diminished network activity occurs in the human brain during aging and in AD, and opposite changes occur in response to activation of N-methyl-D-aspartate (NMDA) and brain-derived neurotrophic factor (BDNF) receptors in cultured cortical neurons and in mice in response to an enriched environment or electroconvulsive shock.
|
20947216 |
2012 |
|
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A sample of AD subjects (N = 341) was genotyped for the BDNF polymorphisms: Val66Met, C270T, and G-712A.
|
19542613 |
2009 |